Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Context: Early palliative care (EPC) is an integral treatment for advanced cancer patients, improving quality of life and symptom management, but the impact of its quality on outcomes is less understood.
Objectives: This study aimed to quantify the quality of EPC and analyze its longitudinal association with depression levels, quality of life (QoL), patient survival, and self-management strategies in patients with advanced cancer.
Methods: This secondary analysis included 144 advanced cancer patients from a randomized controlled trial in South Korea. Participants were stratified into high-quality (N=76) and low-quality (N=68) EPC groups based on Quality Care Questionnaire-Palliative Care scores. Outcomes including QoL (McGill Quality of Life Questionnaire, EORTC QLQ-C15-PAL), depression (PHQ-9), and self-management strategies (SMASH Assessment Tool Short Form) were assessed at baseline, 12, 18, and 24 weeks. Two-year overall survival was analyzed using Kaplan-Meier curves and log-rank tests, while repeated measures used generalized estimating equations and linear mixed-effects models.
Results: The high-quality EPC group demonstrated a significantly lower prevalence of depression at 24 weeks (14.7% vs. 39.1%, p=0.036) and a higher 2-year survival rate (p=0.006) compared to the low-quality group. Significant improvements were observed in existential and social burden (MQOL) and self-management preparation and implementation strategies (SAT-SF) at 18 and 24 weeks in the high-quality EPC group. Overall QoL measured by EORTC QLQ-C15-PAL showed minimal group differences.
Conclusion: The quality of EPC services significantly impacts depression, patient survival, aspects of QoL, and self-management capabilities. These findings emphasize the importance of high-quality EPC beyond mere provision.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jpainsymman.2025.08.031 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Retrospective Study of Pediatric Sinonasal Tumors in a Tertiary Hospital Setting.
Am J Case Rep
September 2025
Department of Otolaryngology - Head and Neck Surgery, King Fahad Specialist Hospital, Dammam, Saudi Arabia.
BACKGROUND Pediatric sinonasal tumors are rare, accounting for about 4% of all pediatric head and neck neoplasms. Due to their nonspecific symptoms such as nasal obstruction, epistaxis, and facial pain, these tumors often present diagnostic challenges and lead to delays in managment. Early and accurate diagnosis is crucial to optimize clinical outcomes.
View Article and Find Full Text PDFDeciphering pancreatobiliary intraductal oncocytic papillary neoplasms: integrative analysis of histomorphologic patterns, immunophenotypic markers, and emerging molecular biomarkers.
World J Surg Oncol
September 2025
Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, No.1 Shuaifuyuan Dongcheng District, Beijing, 100730, China.
Purpose: We reviewed recent advancements in the characterization of intraductal oncocytic papillary neoplasm (IOPN) of the pancreas, with a specific focus on developments in immunohistochemical markers, molecular pathology, and pathogenic mechanisms over the past ten years (2015-2024). Through comprehensive analysis of current literature, we aimed to elucidate the evolving understanding of IOPN's biological behavior and diagnostic features, while identifying potential areas for future research in this distinctive pancreatic neoplasm.
Methods: English-language articles on IOPN were searched from Pubmed from the first report of IOPN of the pancreas in 2015 to 2024.
Prognostic factors of lenvatinib plus pembrolizumab therapy for advanced or recurrent endometrial cancer: analysis of a multicenter cohort study in Japan.
Int J Clin Oncol
September 2025
Department of Obstetrics and Gynecology, The University of Osaka Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan.
Background: Lenvatinib plus pembrolizumab (LP) therapy has emerged as an effective treatment for patients with advanced or recurrent endometrial cancer. However, limited data are available regarding its outcomes in real-world settings. This study aimed to identify prognostic factors associated with the efficacy of LP therapy.
View Article and Find Full Text PDFASO Visual Abstract: SPARC Expression Induces COL1A1/COL3A1 Representing Aggressive Molecular Cancer-Associated Fibroblast Signatures and CSF1-Mediated Cancer Invasion in Colorectal Cancer.
Ann Surg Oncol
September 2025
Division of Advanced Surgical Oncology, Research and Development Center for New Medical Frontiers, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan.
Multicellular tumor-stromal interactions recapitulate aspects of therapeutic response and human oncogenic signaling in a 3D disease model for H3K27M-altered DIPG.
Oncogene
September 2025
Division of Neurosurgery, Children's Hospital Los Angeles, Los Angeles, CA, USA.
It has become evident from decades of clinical trials that multimodal therapeutic approaches with focus on cell intrinsic and microenvironmental cues are needed to improve understanding and treat the rare, inoperable, and ultimately fatal diffuse intrinsic pontine glioma (DIPG), now categorized as a diffuse midline glioma. In this study we report the development and characterization of an in vitro system utilizing 3D Tumor Tissue Analogs (TTA), designed to replicate the intricate DIPG microenvironment. The innate ability of fluorescently labeled human brain endothelial cells, microglia, and patient-derived DIPG cell lines to self-assemble has been exploited to generate multicellular 3D TTAs that mimic tissue-like microstructures, enabling an in- depth exploration of the spatio-temporal dynamics between neoplastic and stromal cells.
View Article and Find Full Text PDF